RUNX1 and acute lymphoblastic leukemia: The detection of specific chromosome aberrations and fusion genes is important, as it can be used to assign B-ALL patients to targeted therapy, for example, BCR-ABL1 t(9;22)(q34;q11.2) is amenable to tyrosine kinase inhibitors [23] or can be informative of a good prognosis (i.e., ETV6-RUNX1 t(12;21)(p13;q22)) [80].